TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $43.00 at JPMorgan Chase & Co.

TG Therapeutics (NASDAQ:TGTX) had its price target upped by JPMorgan Chase & Co. from $30.00 to $43.00 in a research report report published on Monday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the stock. TD Cowen began coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. B. Riley lifted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. HC Wainwright increased their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, The Goldman Sachs Group lifted their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Stock Up 2.2 %

Shares of NASDAQ:TGTX opened at $35.00 on Monday. TG Therapeutics has a 1 year low of $12.32 and a 1 year high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock’s 50-day moving average is $26.00 and its 200 day moving average is $21.95. The company has a market cap of $5.45 billion, a PE ratio of -342.57 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics’s revenue was down 49.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.73 EPS. Sell-side analysts anticipate that TG Therapeutics will post 0.17 EPS for the current year.

Insider Activity

In other news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Large investors have recently modified their holdings of the stock. NBC Securities Inc. grew its position in TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the last quarter. Quarry LP lifted its stake in shares of TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 503 shares in the last quarter. Private Advisor Group LLC grew its holdings in shares of TG Therapeutics by 3.9% during the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 542 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 849 shares during the last quarter. Finally, KBC Group NV increased its position in shares of TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,092 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.